4 results  1 of 1 

1 Impact of COVID-19 on Clinicopathological Spectrum of Pityriasis Rosea in Korea
Dai Hyun Kim, Jun Hyuk Cho, Sung Jin Park, Soo Hong Seo, Hyo Hyun Ahn
J Korean Med Sci.2022;37(24):e190.  Published online 2022 June 3     DOI: http://dx.doi.org/10.3346/jkms.2022.37.e190
      
2 Higher Expression of Toll-like Receptors 3, 7, 8, and 9 in Pityriasis Rosea
Mostafa Abou El-Ela, Mohamed El-Komy, Rania Abdel Hay, Rehab Hegazy, Amin Sharobim, Laila Rashed, Khalda Amr
J Pathol Transl Med.2017;51(2):148-151.   Published online 2017 February 13     DOI: http://dx.doi.org/10.4132/jptm.2016.09.09
      
3 Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
Ah Young Cho, Dae Hun Kim, Myung Im, Young Lee, Young Joon Seo, Jeung Hoon Lee
Ann Dermatol.2011;23(Suppl 3):S360-S363.   Published online 2011 December 27     DOI: http://dx.doi.org/10.5021/ad.2011.23.S3.S360
      
4 Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea
Sang Hee Lim, Sang Min Kim, Byung Ho Oh, Jong Hyun Ko, Yang Won Lee, Yong Beom Choe, Kyu Joong Ahn
Ann Dermatol.2009;21(3):230-236.   Published online 2009 August 31     DOI: http://dx.doi.org/10.5021/ad.2009.21.3.230
      

 1 of 1